Overview
- Fresenius reported Q2 revenue of €5.86 billion, a currency-adjusted EBIT increase of 10% to €719 million, and a net profit of €470 million.
- The company raised its full-year core earnings-per-share guidance to a rise of 10–15% for 2026 from a prior range of 5–10%.
- Management said the result was driven by particularly strong biopharma performance at Fresenius Kabi and by Helios hospitals benefiting from the Rechnungszuschlag billing rule.
- CEO Michael Sen credited the gains to his restructuring program that began in 2022, which included selling non-core units such as Eugin, slimming group structures and separating operational ties with Fresenius Medical Care while keeping FMC as a financial investment.
- The upgrade highlights improved operating cash flow and a better interest result but leaves open two watchpoints for investors: whether Helios’s billing boost is sustainable and whether Kabi’s biopharma momentum will persist.